ALICE MAO: Open Payments
NPI 1851309488 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$170,127 in 276 payments from 23 companies in 2025. Trend: 2023 $171,732 · 2024 $129,350 · 2025 $170,127
Speaker / faculty: $85,455Honoraria: $58,360Travel & lodging: $20,169Food & beverage: $6,143
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 97 | $94,202 |
| Supernus Pharmaceuticals, Inc. | 63 | $56,559 |
| Tris Pharma Inc | 27 | $16,823 |
| Vanda Pharmaceuticals Inc. | 12 | $422 |
| Axsome Therapeutics, Inc. | 12 | $310 |
| Neurocrine BioSciences, Inc. | 9 | $224 |
| ABBVIE INC. | 12 | $218 |
| Teva Pharmaceuticals USA, Inc. | 2 | $215 |
| Corium, LLC | 7 | $187 |
| E.R. Squibb & Sons, L.L.C. | 2 | $154 |
Products named: REXULTI, Qelbree, Dyanavel XR, FANAPT, Auvelity, Onyda XR, INGREZZA, VRAYLAR.
Industry payments across TX — which companies pay providers there.
